Skip to main content
Log in

Pharmacokinetics of cimetidine after subchronic administration

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The influence of cimetidine on its own pharmacokinetics after subchronic administration was assessed in 8 healthy volunteers, aged 26–29 years. On control Day 1, each subject received cimetidine 300 mg i.v., and serum and urine samples were obtained. Each subject was initiated on cimetidine 600 mg b.i.d. orally for 2 weeks. There were 3 further study days repeated after 1 and 2 weeks of cimetidine dosing and 1 week after stopping cimetidine. There was no significant difference in the mean total body clearance of cimetidine among the 4 study days. Mean elimination t1/2β and Vβ were similarly unchanged. However mean renal clearance (CLR) and fe were significantly increased following 2 weeks of drug dosing (CLR 5.41 ml·min−1 kg−1; fe 0.61) compared to control (CLR 4.00 ml·min−1·kg−1; fe 0.48). Although the non renal clearance was reduced from control values of 4.29 to 3.51 ml·min−1·kg−1 following 2 weeks of dosing the difference was not significant. Dosage adjustment of cimetidine appears unnecessary after short-term dosing in the presence of normal renal function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Guay DRP, Matzke GR, Bockbrader HN et al. (1983) Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function. Clin Pharm 2: 157–162

    Google Scholar 

  2. Somogyi A, Rohner HG, Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 5: 84–94

    Google Scholar 

  3. Larsson R, Erlanson P, Bodemar G et al. (1982) The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol 13: 163–170

    Google Scholar 

  4. Grahnen A, von Bahr C, Lindstrom B et al. (1979) Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol 16: 335–340

    Google Scholar 

  5. Burland WL, Duncan WAM, Hesselbo T et al. (1975) Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy mean. Br J Clin Pharmacol 2: 481–486

    Google Scholar 

  6. Schentag JJ, Cerra FB, Calleri GM et al. (1981) Age, disease and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 29: 737–743

    Google Scholar 

  7. Taylor DC, Cresswell PR, Bartlett DC (1978) The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist in the rat, dog and man. Drug Metab Dispos 6: 21–30

    Google Scholar 

  8. Sedman AJ (1984) Cimetidine-drug interactions. Am J Med 76: 109–114

    Google Scholar 

  9. Somogyi A, Gugler A (1982) Drug interactions with cimetidine. Clin Pharmacokinet 7: 23–41

    Google Scholar 

  10. Soldin SJ, Fingold DR, Fenje PC et al. (1979) High performance liquid chromatographic analysis of cimetidine in serum. Ther Drug Monitor 1: 371–379

    Google Scholar 

  11. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York

    Google Scholar 

  12. Lebert PA, Mahon WA, MacLeod SM et al. (1981) Ranitidine kinetics and dynamics. II. Intravenous dose studies and comparison with cimetidine. Clin Pharmacol Ther 30: 545–550

    Google Scholar 

  13. Bodemar G, Norlander B, Walan A (1981) Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet 6: 306–315

    Google Scholar 

  14. Mantyl R, Klinge E, Nykanen S et al. (1980) Pharmacokinetics of single and multiple oral doses of cimetidine in healthy nonfasting volunteers. Naunyn Schmiedebergs Arch Pharmacol 313 [Suppl]: R54

  15. Bodemar G, Norlander B, Fransson L et al. (1979) The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine-studies in patients with peptic ulcer disease. Br J Clin Pharmacol 7: 23–31

    Google Scholar 

  16. Webster J, Barber HE, Hawksworth GM et al. (1981) Cimetidine — a clinical and pahrmacokinetic study. Br J Clin Pharmacol 11: 333–338

    Google Scholar 

  17. Mihaly GW, Jones DB, Anderson JA et al. (1984) Pharmacokinetic studies of cimetidine and ranitidine before and after treatment in peptic ulcer patients. Br J Clin Pharmacol 17: 109–111

    Google Scholar 

  18. Patwardhan RV, Johnson RF, Sinclair AP et al. (1981) Lack of tolerance and rapid recovery of cimetidine-inhibited chlordiazepoxide (Librium) elimination. Gastroenterol 81: 547–551

    Google Scholar 

  19. Vestal RE, Thummel KE, Musser B (1983) Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease — a study using stable isotope methodology during multiple oral dose administration. Br J Clin Pharmacol 15: 411–418

    Google Scholar 

  20. Speeg KV, Patwardhan RV, Avant GR et al. (1982) Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterol 82: 89–96

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chin, T.W.F., Spino, M., MacLeod, S.M. et al. Pharmacokinetics of cimetidine after subchronic administration. Eur J Clin Pharmacol 30, 741–744 (1986). https://doi.org/10.1007/BF00608228

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00608228

Key words

Navigation